Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YMCJB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
anti-TRBC1-MMAE
|
|||||
| Synonyms |
anti-TRBC1-MMAE
Click to Show/Hide
|
|||||
| Organization |
THE JOHNS HOPKINS UNIVERSITY[US/US]
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.22
|
|||||
| Structure |
|
|||||
| Antibody Name |
undisclosed
|
|||||
| Antigen Name |
T cell receptor beta-chain constant region 1 (TRBC1)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.125 nM
|
|||
| Method Description |
IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in CML-T1 TRBC1
|
||||
| In Vitro Model | Chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia | CML-T1 TRBC1 cells | CVCL_1126 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.141 nM
|
|||
| Method Description |
IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in Jurkat TRBC2
|
||||
| In Vitro Model | Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia | Jurkat TRBC2 cells | CVCL_0065 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.144 nM
|
|||
| Method Description |
IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in Jurkat TCR-KO
|
||||
| In Vitro Model | Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia | Jurkat TCR-KO cells | CVCL_0065 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.145 nM
|
|||
| Method Description |
IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in Jurkat TRBC1
|
||||
| In Vitro Model | Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia | Jurkat TRBC1 cells | CVCL_0065 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.155 nM
|
|||
| Method Description |
IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in HPB-ALL TRBC2
|
||||
| In Vitro Model | Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia | HPB-ALL TRBC2 cells | CVCL_1820 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.156 nM
|
|||
| Method Description |
IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in HPB-ALL TRBC1
|
||||
| In Vitro Model | Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia | HPB-ALL TRBC1 cells | CVCL_1820 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.248 nM
|
|||
| Method Description |
IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in SUP-T1 TRBC1
|
||||
| In Vitro Model | Childhood T lymphoblastic lymphoma, T-cell non-Hodgkin lymphoma | SUP-T1 TRBC1 cells | CVCL_1714 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.611 nM
|
|||
| Method Description |
IC50 Values (nM) of anti-TRBC1-MMAE in T-cell cancer cell lines in H9 TRBC1
|
||||
| In Vitro Model | Sezary syndrome | H9 TRBC1 cells | CVCL_1240 | ||